Rigosertib Formulation Stability via Basic pH and Low Water Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Rigosertib formulations with water-soluble polymers like PEG 400 suffer from stability issues, impurity formation, and urothelial toxicity, requiring improved stability and bioavailability for effective cancer treatment.
Innovation Solution
Pharmaceutical compositions of Rigosertib with basic pre-treated low molecular weight polyethylene glycol (PEG) at an undiluted pH of 11.0 to 14.0 and less than 5% water or aqueous solution, reducing impurities and enhancing oral bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Rigosertib is formulated with water-soluble polymers like PEG 400 and aqueous buffers, then solubility is improved, but stability deteriorates and impurity levels increase
Solution Approach 1:
The patent applies parameter changes by adjusting the pH to a basic range (pH 10-14) and controlling water content at low levels (0-5%). This transforms the formulation from an aqueous-based system to a non-aqueous basic system, which resolves the contradiction by maintaining solubility through high pH while achieving stability through low water content and basic conditions that prevent degradation and impurity formation.
2Stability of the object's composition
If Rigosertib is stored under refrigeration to maintain stability, then stability is improved, but ease of operation deteriorates and expense increases
Solution Approach 1:
The patent changes the formulation parameters to basic pH (10-14) and low water content (0-5%), which fundamentally alters the stability profile of Rigosertib. This enables the drug to be stored at room temperature instead of requiring refrigeration, thereby improving ease of operation and reducing expenses while maintaining stability through the chemically optimized formulation environment.
3Ease of operation
If Rigosertib is administered orally, then ease of operation is improved, but urothelial toxicity increases
Solution Approach 1:
The patent employs parameter changes in the formulation (basic pH 10-14, low water content 0-5%, use of basic pre-treated PEG) that modify the chemical properties of Rigosertib. These changes reduce the drug's irritant effects on urothelial tissue, enabling oral administration to proceed with reduced toxicity while maintaining ease of operation.
4Stability of the object's composition
If Rigosertib is formulated in PEG 400 with phosphate buffer at high pH, then stability is improved, but crystal formation occurs
Solution Approach 1:
The patent adjusts multiple parameters simultaneously: using basic pre-treated PEG 400, maintaining pH 10-14, and critically limiting water content to 0-5%. This combination of parameters prevents crystal formation by maintaining the drug in a dissolved state through the basic non-aqueous environment, while still achieving stability through the controlled chemical conditions.
Data Source
AI summary
Pharmaceutical compositions of (E)-2,4,6-trimethoxy styryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone and pharmaceutically acceptable salts thereof are described as well as methods of their use, and a dose regimen of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone, sodium salt to reduce the incidence of urothelial toxicity.